title: Bevacizumab in the therapy for refractory metastatic colorectal cancer.
abstract: Colorectal cancer is the second most common cause of cancer related deaths in the United States. Recent developments have led to prolonged survival with the use of sequential lines of chemotherapy agents. The addition of bevacizumab to active chemotherapy has further improved survival when used in the first and second lines of therapy for metastatic colorectal cancer. Evidence supporting the continued use of bevacizumab throughout lines of therapy is accumulating. Clinical trials are underway in which bevacizumab is continued beyond the first line of a chemotherapy and bevacizumab combination regimen. The mechanism by which colorectal cancer may become resistant to bevacizumab is poorly understood. Molecular and biochemical correlates which may identify bevacizumab resistance are an important component in the design of these clinical trials.
authors.affiliation: Northwestern University, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Chicago IL, USA.
authors.forename: Mary F
authors.initials: MF
authors.lastname: Mulcahy
references.citation: Nature. 1993 Apr 29;362(6423):841-4
references.pmid: 7683111
references.citation: J Clin Oncol. 2006 Jan 20;24(3):394-400
references.pmid: 16421419
references.citation: J Clin Pathol. 2004 May;57(5):504-12
references.pmid: 15113858
references.citation: J Clin Oncol. 2004 Jan 15;22(2):229-37
references.pmid: 14657227
references.citation: Expert Opin Investig Drugs. 2002 Dec;11(12):1715-36
references.pmid: 12457433
references.citation: J Clin Oncol. 2005 Aug 1;23(22):4866-75
references.pmid: 15939922
references.citation: N Engl J Med. 2003 Jul 31;349(5):427-34
references.pmid: 12890841
references.citation: J Clin Oncol. 2003 Jun 1;21(11):2059-69
references.pmid: 12775730
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3697-705
references.pmid: 15738537
references.citation: J Clin Oncol. 2006 Jul 20;24(21):3354-60
references.pmid: 16849749
references.citation: Sci Am. 1994 Jul;271(1):58-65
references.pmid: 8066425
references.citation: J Clin Oncol. 2000 Aug;18(16):2938-47
references.pmid: 10944126
references.citation: Clin Colorectal Cancer. 2006 May;6(1):66-9
references.pmid: 16796794
references.citation: Lancet. 2000 Mar 25;355(9209):1041-7
references.pmid: 10744089
references.citation: J Clin Oncol. 2004 Jan 1;22(1):23-30
references.pmid: 14665611
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1209-14
references.pmid: 15051767
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1539-44
references.pmid: 17442997
references.citation: Eur J Cancer. 2001 May;37(8):1000-5
references.pmid: 11334725
references.citation: Lancet. 1998 Oct 31;352(9138):1413-8
references.pmid: 9807987
references.citation: Science. 2005 Jan 7;307(5706):58-62
references.pmid: 15637262
references.citation: Lancet. 1998 Oct 31;352(9138):1407-12
references.pmid: 9807986
references.citation: J Clin Oncol. 2007 Oct 10;25(29):4557-61
references.pmid: 17876013
references.citation: J Clin Oncol. 2006 Jan 10;24(2):217-27
references.pmid: 16365183
references.citation: Endocr Rev. 1997 Feb;18(1):4-25
references.pmid: 9034784
references.citation: J Clin Oncol. 2005 Jun 1;23(16):3706-12
references.pmid: 15867200
references.citation: Ann Oncol. 2000 Nov;11(11):1477-83
references.pmid: 11142489
references.citation: Nat Med. 2004 Feb;10(2):145-7
references.pmid: 14745444
references.citation: N Engl J Med. 2000 Sep 28;343(13):905-14
references.pmid: 11006366
references.citation: Oncologist. 2000;5 Suppl 1:11-5
references.pmid: 10804085
references.citation: N Engl J Med. 2004 Jul 22;351(4):337-45
references.pmid: 15269313
references.citation: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references.pmid: 17237035
references.citation: J Natl Cancer Inst. 2005 Jul 6;97(13):981-9
references.pmid: 15998951